Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations

Xuewen Liu, Yuxia Jia, Mark B. Stoopler, Yufeng Shen, Haiying Cheng, Jinli Chen, Mahesh Mansukhani, Sanjay Koul, Balazs Halmos, Alain C. Borczuk

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

Purpose: To further understand the molecular pathogenesis of pulmonary sarcomatoid carcinoma (PSC) and develop new therapeutic strategies in this treatment-refractory disease. Materials and Methods: Whole-exome sequencing in a discovery set (n510) as well as targetedMET mutation screening in an independent validation set (n = 26) of PSC were performed. Reverse transcriptase polymerase chain reaction and Western blotting were performed to validate MET exon 14 skipping. Functional studies for validation of the oncogenic roles of MET exon 14 skippingwere conducted in lung adenosquamous cell line H596 (MET exon 14 skipped and PIK3CA mutated) and gastric adenocarcinoma cell line Hs746T (MET exon 14 skipped). Response to MET inhibitor therapy with crizotinib in a patient with advanced PSC and MET exon 14 skipping was evaluated to assess clinical translatability. Results: In addition to confirming mutations in known cancer-associated genes (TP53, KRAS, PIK3CA, MET, NOTCH, STK11, and RB1), several novel mutations in additional genes, including RASA1, CDH4, CDH7, LAMB4, SCAF1, and LMTK2, were identified and validated. MET mutations leading to exon 14 skipping were identified in eight (22%) of 36 patient cases; one of these tumors also harbored a concurrent PIK3CA mutation. Short interfering RNA silencing of MET and MET inhibition with crizotinib showed marked effects on cell viability and decrease in downstream AKT and mitogen-activated protein kinase activation in Hs746T and H596 cells. Concurrent PIK3CA mutation required addition of a second agent for successful pathway suppression and cell viability effect. Dramatic response to crizotinib was noted in a patient with advanced chemotherapy-refractory PSC carrying a MET exon 14 skipping mutation. Conclusion: Mutational events of MET leading to exon 14 skipping are frequent and potentially targetable events in PSC.

Original languageEnglish (US)
Pages (from-to)794-802
Number of pages9
JournalJournal of Clinical Oncology
Volume34
Issue number8
DOIs
StatePublished - Mar 10 2016

Fingerprint

Exons
Carcinoma
Lung
Mutation
Genes
Cell Survival
Exome
Cell Line
Validation Studies
Neoplasm Genes
RNA Interference
Mitogen-Activated Protein Kinases
Reverse Transcriptase Polymerase Chain Reaction
Small Interfering RNA
Stomach
Adenocarcinoma
Therapeutics
Western Blotting
Drug Therapy
crizotinib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. / Liu, Xuewen; Jia, Yuxia; Stoopler, Mark B.; Shen, Yufeng; Cheng, Haiying; Chen, Jinli; Mansukhani, Mahesh; Koul, Sanjay; Halmos, Balazs; Borczuk, Alain C.

In: Journal of Clinical Oncology, Vol. 34, No. 8, 10.03.2016, p. 794-802.

Research output: Contribution to journalArticle

Liu, Xuewen ; Jia, Yuxia ; Stoopler, Mark B. ; Shen, Yufeng ; Cheng, Haiying ; Chen, Jinli ; Mansukhani, Mahesh ; Koul, Sanjay ; Halmos, Balazs ; Borczuk, Alain C. / Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. In: Journal of Clinical Oncology. 2016 ; Vol. 34, No. 8. pp. 794-802.
@article{677b0224e7c44edd93b2d531bbe39479,
title = "Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations",
abstract = "Purpose: To further understand the molecular pathogenesis of pulmonary sarcomatoid carcinoma (PSC) and develop new therapeutic strategies in this treatment-refractory disease. Materials and Methods: Whole-exome sequencing in a discovery set (n510) as well as targetedMET mutation screening in an independent validation set (n = 26) of PSC were performed. Reverse transcriptase polymerase chain reaction and Western blotting were performed to validate MET exon 14 skipping. Functional studies for validation of the oncogenic roles of MET exon 14 skippingwere conducted in lung adenosquamous cell line H596 (MET exon 14 skipped and PIK3CA mutated) and gastric adenocarcinoma cell line Hs746T (MET exon 14 skipped). Response to MET inhibitor therapy with crizotinib in a patient with advanced PSC and MET exon 14 skipping was evaluated to assess clinical translatability. Results: In addition to confirming mutations in known cancer-associated genes (TP53, KRAS, PIK3CA, MET, NOTCH, STK11, and RB1), several novel mutations in additional genes, including RASA1, CDH4, CDH7, LAMB4, SCAF1, and LMTK2, were identified and validated. MET mutations leading to exon 14 skipping were identified in eight (22{\%}) of 36 patient cases; one of these tumors also harbored a concurrent PIK3CA mutation. Short interfering RNA silencing of MET and MET inhibition with crizotinib showed marked effects on cell viability and decrease in downstream AKT and mitogen-activated protein kinase activation in Hs746T and H596 cells. Concurrent PIK3CA mutation required addition of a second agent for successful pathway suppression and cell viability effect. Dramatic response to crizotinib was noted in a patient with advanced chemotherapy-refractory PSC carrying a MET exon 14 skipping mutation. Conclusion: Mutational events of MET leading to exon 14 skipping are frequent and potentially targetable events in PSC.",
author = "Xuewen Liu and Yuxia Jia and Stoopler, {Mark B.} and Yufeng Shen and Haiying Cheng and Jinli Chen and Mahesh Mansukhani and Sanjay Koul and Balazs Halmos and Borczuk, {Alain C.}",
year = "2016",
month = "3",
day = "10",
doi = "10.1200/JCO.2015.62.0674",
language = "English (US)",
volume = "34",
pages = "794--802",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations

AU - Liu, Xuewen

AU - Jia, Yuxia

AU - Stoopler, Mark B.

AU - Shen, Yufeng

AU - Cheng, Haiying

AU - Chen, Jinli

AU - Mansukhani, Mahesh

AU - Koul, Sanjay

AU - Halmos, Balazs

AU - Borczuk, Alain C.

PY - 2016/3/10

Y1 - 2016/3/10

N2 - Purpose: To further understand the molecular pathogenesis of pulmonary sarcomatoid carcinoma (PSC) and develop new therapeutic strategies in this treatment-refractory disease. Materials and Methods: Whole-exome sequencing in a discovery set (n510) as well as targetedMET mutation screening in an independent validation set (n = 26) of PSC were performed. Reverse transcriptase polymerase chain reaction and Western blotting were performed to validate MET exon 14 skipping. Functional studies for validation of the oncogenic roles of MET exon 14 skippingwere conducted in lung adenosquamous cell line H596 (MET exon 14 skipped and PIK3CA mutated) and gastric adenocarcinoma cell line Hs746T (MET exon 14 skipped). Response to MET inhibitor therapy with crizotinib in a patient with advanced PSC and MET exon 14 skipping was evaluated to assess clinical translatability. Results: In addition to confirming mutations in known cancer-associated genes (TP53, KRAS, PIK3CA, MET, NOTCH, STK11, and RB1), several novel mutations in additional genes, including RASA1, CDH4, CDH7, LAMB4, SCAF1, and LMTK2, were identified and validated. MET mutations leading to exon 14 skipping were identified in eight (22%) of 36 patient cases; one of these tumors also harbored a concurrent PIK3CA mutation. Short interfering RNA silencing of MET and MET inhibition with crizotinib showed marked effects on cell viability and decrease in downstream AKT and mitogen-activated protein kinase activation in Hs746T and H596 cells. Concurrent PIK3CA mutation required addition of a second agent for successful pathway suppression and cell viability effect. Dramatic response to crizotinib was noted in a patient with advanced chemotherapy-refractory PSC carrying a MET exon 14 skipping mutation. Conclusion: Mutational events of MET leading to exon 14 skipping are frequent and potentially targetable events in PSC.

AB - Purpose: To further understand the molecular pathogenesis of pulmonary sarcomatoid carcinoma (PSC) and develop new therapeutic strategies in this treatment-refractory disease. Materials and Methods: Whole-exome sequencing in a discovery set (n510) as well as targetedMET mutation screening in an independent validation set (n = 26) of PSC were performed. Reverse transcriptase polymerase chain reaction and Western blotting were performed to validate MET exon 14 skipping. Functional studies for validation of the oncogenic roles of MET exon 14 skippingwere conducted in lung adenosquamous cell line H596 (MET exon 14 skipped and PIK3CA mutated) and gastric adenocarcinoma cell line Hs746T (MET exon 14 skipped). Response to MET inhibitor therapy with crizotinib in a patient with advanced PSC and MET exon 14 skipping was evaluated to assess clinical translatability. Results: In addition to confirming mutations in known cancer-associated genes (TP53, KRAS, PIK3CA, MET, NOTCH, STK11, and RB1), several novel mutations in additional genes, including RASA1, CDH4, CDH7, LAMB4, SCAF1, and LMTK2, were identified and validated. MET mutations leading to exon 14 skipping were identified in eight (22%) of 36 patient cases; one of these tumors also harbored a concurrent PIK3CA mutation. Short interfering RNA silencing of MET and MET inhibition with crizotinib showed marked effects on cell viability and decrease in downstream AKT and mitogen-activated protein kinase activation in Hs746T and H596 cells. Concurrent PIK3CA mutation required addition of a second agent for successful pathway suppression and cell viability effect. Dramatic response to crizotinib was noted in a patient with advanced chemotherapy-refractory PSC carrying a MET exon 14 skipping mutation. Conclusion: Mutational events of MET leading to exon 14 skipping are frequent and potentially targetable events in PSC.

UR - http://www.scopus.com/inward/record.url?scp=84962609567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962609567&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.62.0674

DO - 10.1200/JCO.2015.62.0674

M3 - Article

C2 - 26215952

AN - SCOPUS:84962609567

VL - 34

SP - 794

EP - 802

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -